Oncolytics Biotech Inc. February 2025 Form 6-K Report: Key Updates & Compliance

Here are the key insights extracted from the provided section of the financial report:

1. Document Type and Filing Information:

• The document is a Form 6-K, which is a report of a foreign private issuer.
• It has been filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.

2. Report Period:

• The report covers the month of February 2025.

3. Company Information:

• The registrant is Oncolytics Biotech Inc., located at Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5.
• The document includes the translation of the registrant's name into English.

4. Commission File Number:

• The Commission File Number is 001-38512.

5. Regulatory Compliance:

• The report indicates whether the registrant files or will file annual reports under Form 20-F or Form 40-F.
• There are checkboxes to indicate compliance with Regulation S-T rules regarding the submission of Form 6-K in paper format.

6. Exhibit Information:

• The report includes an exhibit labeled 99.1, which is a press release. This is significant as it is likely to contain additional context or important updates regarding company activities.

7. Signature and Authorization:

• The report is signed by Kirk Look, Chief Financial Officer, which signifies that the information provided is accurate and authorized by the company's management.
• The date of the signature is February 14, 2025.

8. Note on Submission Rules:

• The document includes notes on the conditions under which Form 6-K may be submitted in paper format, emphasizing compliance with specific regulatory requirements.

Overall, this document serves as a formal communication to the SEC, providing updates on Oncolytics Biotech Inc. and confirming adherence to regulatory requirements. The inclusion of a press release indicates possible significant developments or announcements from the company during the reported period.